Standout Papers

Ubrogepant for the Treatment of Migraine 2019 2026 2021 2023 248
  1. Ubrogepant for the Treatment of Migraine (2019)
    David W. Dodick, Richard B. Lipton et al. New England Journal of Medicine
  2. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial (2023)
    Patricia Pozo‐Rosich, Jessica Ailani et al. The Lancet

Citation Impact

1 by Nobel laureates 8 from Science/Nature 60 standout
Sub-graph 1 of 19

Citing Papers

Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
2 intermediate papers

Works of Kaifeng Lu being referenced

Comparison Between Two Controlled Multiple Imputation Methods for Sensitivity Analyses of Time-to-Event Data With Possibly Informative Censoring
2015
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
2006

Author Peers

Author PMh SP MSOR PFM Physiology Last Decade Papers Cites
Kaifeng Lu 1788 317 41 613 480 85 3.1k
D. Griffin 29 2 97 31 30 414
Abu Osman Md Tap 6 18 19 116
Joel Taylor 4 24 256
Itxaso Azcune 26 973
So Kawata 15 991

All Works

Loading papers...

Rankless by CCL
2026